Varicella Vaccine Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Varicella Vaccine Market Analysis
The varicella vaccine market is expected to register a CAGR of 5.6% during the forecast period, 2022-2027.
The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease has been linked to T-cell immunological dysfunction. Herpes zoster reactivation could be brought on by COVID-19 infection. According to the study titled "Can, COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review" published in the Dermatology and therapy in August 2021, Varicella-zoster virus reactivation on COVID-19 patients can be brought on by T cell dysfunction, such as lymphopenia and lymphocyte depletion. Due to COVID-19's propensity to develop an immunosuppressive state, which is linked to the functional impairment and concurrent quantitative decline in T lymphocytes, particularly CD4+ T cells, CD8+ T cells, and natural killer cells, patients with COVID-19 are more likely to experience reactivation of herpes zoster. Moreover, according to the study titled "Herpes zoster in the era of COVID 19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination" published in the National Library of Medicine in June 2022, reported that during post-marketing surveillance, reactivation of the varicella-zoster virus has occasionally been reported following vaccination for SARS-CoV-2. Therefore, during the ongoing COVID-19 outbreak, managing varicella infection has become more crucial.
The market is driven by the rising prevalence of the target diseases, growing awareness regarding the use of the varicella vaccine, and an increase in immunization programs across the world. For Instance, In August 2020, GSK reported the launch of DT campaign for shingrix vaccine targeted against the aging for vaccination against vericella. Similatly, as per the National Health Mission in July 2022, One of the biggest public health initiatives, the Universal Immunization Program (UIP), targets nearly 2.67 billion newborns and 2.9 billion expectant mothers each year against diseases including measles, rubella, chickenpox, and other. Thus, a growing immunization program against the varicella zoster is expected to drive the demand for varicella vaccines thereby boosting the market growth.
However, the growing prevalence of varicella or chickenpox is anticipated to drive the growth of the market. For instance, according to the study titled "Epidemiological analysis of varicella in Dalian from 2009 to 2019 and application of three kinds of the model in prediction prevalence of varicella' published in the BMC Public Health in April 2022, the prevalence was 50.56/100000 on a yearly average. The bimodal distribution of varicella was constant throughout the year. Moreover, according to the Center for Diseases Control and Prevention in May 2021, Herpes zoster affects people 60 and older at a rate of about 1 case per 100 in the U.S. each year, and 1 to 4% of patients end up in hospitals for complications, 30% of whom have weakened immune systems. Elderly people are more prone to herpes zoster due to weakened immune systems. However, the high cost of vaccines restraint the market growth.
Furthermore, growing awareness regarding varicella vaccine usage, active participation of the government in immunization programs, and a surge in the acceptance of varicella vaccines are the key driving factors in the varicella vaccine market. However, high cost of the vaccine restraint the market growth.
Varicella Vaccine Market Trends
This section covers the major market trends shaping the Varicella Vaccine Market according to our research experts:
Monovalent Varicella Vaccine Segment is Expected to Hold a Significant Market Share in the Varicella Vaccine Market
The monovalent varicella vaccine segment holds a significant market share in the varicella vaccine market and is anticipated to show a similar trend over the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children compared to combination vaccines. The monovalent vaccines contain a single strain of a single varicella live vaccine, contains a weakened strain of the varicella-zoster virus.
These vaccines are used for chickenpox immunization and herpes zoster immunization hence growing prevalence of these diseases is anticipated to drive the growth of the market. According to the study titled "Geospatial Epidemiology of chicken-pox disease in India between 2015-2021: A GIS based analysis" published in the National Journal of Indian Association of Preventive and Social Medicine, March 2021, There have been 1269 outbreaks of chickenpox between January 2015 and May 2021, totaling 27,257 cases. The confirmed death toll stands at 31, with Bihar and Uttar Pradesh accounting for the majority of cases. 19 states did not report any fatalities. The seasonally adjusted trend indicates that January and March saw the highest number of cases. Thus, growing prevalence of the chickenpox expected to drive the demand for vericella vaccines thereby boost the market growth.
Moreover, according to the study titled "Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries" published in Vaccines in May 2021, Following varicella immunisation, one dosage induced antibody responses that lasted for ten years. Thus, due to such benefits of the monovalent vericella vaccines drives the growth of the segment
Furthermore, easy availability and high adoption of monovalent products are the key driving factors in the monovalent varicella vaccine segment.
North America is Expected to Hold a Significant Share in the Market and it is Expected to do the Same during the Forecast Period
The North American region is expected to hold a major market share of the global varicella vaccine market, due to the presence of major players involved in the commercialization and development of vaccines in this region. According to the Centers for Disease Control and Prevention (CDC) update in April 2020, estimates, more than 3.5 million cases of varicella, 9,000 hospitalizations, and around 100 deaths are prevented by varicella vaccination each year in the United States. Furthermore, the presence of a well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.
However, there are numerous campaigns being conducted in the United States to immunize people against the vericella vaccine in order to prevent diseases. For Instance, in October 2021, Measles, mumps, rubella (MMR), and varicella (chickenpox) vaccinations for Afghan evacuees who are temporarily staying at eight military installations in the United States have been administered nationwide as part of Operation Allies Welcome (OAW). This effort has resulted in the vaccination of more than 49,000 Afghan refugees nationwide. Additionally, vaccinations are being given to evacuees at staging locations in Europe and the Middle East.
Through various clinical trials, major corporations are concentrating on creating and marketing safe and efficient vaccines to treat herpes zoster infection. For Instance, In November 2021, GlaxoSmithKline Inc. reported that SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Additionally, the market is likely to grow throughout the forecast period due to increased government funding for vaccination and awareness programmes.
Thus, owing to the above-mentioned factors, it is expected to aid the growth of the market studied in the North American region over the forecast period.
Varicella Vaccine Industry Overview
The varicella vaccine market is consolidated and consists of a few major players. Some of the prominent players operating in the varicella vaccine market are GlaxoSmithKline PLC, Merck & Co. Inc., GC Pharma (Green Cross Holdings), Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, Sanofi, Takeda Pharmaceutical Company Limited, and Mitsubishi Tanabe Pharma Corporation.
Varicella Vaccine Market Leaders
-
GlaxoSmithKline Plc
-
Merck & Co., Inc
-
GC Pharma (Green Cross Holdings)
-
Bio-Med Pvt. Limited
-
Novo Medi Sciences Pvt. Ltd
*Disclaimer: Major Players sorted in no particular order
Varicella Vaccine Market News
- In January 2022, Pfizer Inc. and BioNTech SE reported a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
- In July 2021, GlaxoSmithKline plc reported that the United States Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted), to prevent herpes zoster in adults aged 18 and above who are at higher risk of developing the disorder due to immunodeficiency.
Varicella Vaccine Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness Regarding the Use of Varicella Vaccine
4.2.2 Increase in Immunization Programs Across the World
4.3 Market Restraints
4.3.1 High Cost of the Vaccine
4.3.2 Time-consuming Process for the Development of Varicella Vaccine
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size By Value - USD Million)
5.1 By Vaccine
5.1.1 Monovalent Varicella Vaccine
5.1.2 Combination Varicella Vaccine
5.2 By Application
5.2.1 Chickenpox Immunization
5.2.2 Herpes Zoster Immunization
5.2.3 Mumps, Measles, Rubella, and Varicella Immunization
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Merck & Co. Inc.
6.1.3 GC Pharma (Green Cross Holdings)
6.1.4 Bio-Med Pvt Ltd
6.1.5 Novo Medi Sciences Pvt Ltd
6.1.6 Sanofi
6.1.7 Takeda Pharmaceutical Company Limited
6.1.8 Mitsubishi Tanabe Pharma Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Varicella Vaccine Industry Segmentation
As per the scope of the report, varicella or chickenpox is an acute and highly contagious disease caused by the varicella-zoster virus, which is a member of the herpes family. It usually occurs during childhood and is very contagious. The Market is Segmented by Vaccine Type (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, Mumps, Measles, Rubella, and Varicella Immunization), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Vaccine | |
| Monovalent Varicella Vaccine | |
| Combination Varicella Vaccine |
| By Application | |
| Chickenpox Immunization | |
| Herpes Zoster Immunization | |
| Mumps, Measles, Rubella, and Varicella Immunization |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Varicella Vaccine Market Research FAQs
What is the current Global Varicella Vaccine Market size?
The Global Varicella Vaccine Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Global Varicella Vaccine Market?
GlaxoSmithKline Plc, Merck & Co., Inc, GC Pharma (Green Cross Holdings), Bio-Med Pvt. Limited and Novo Medi Sciences Pvt. Ltd are the major companies operating in the Global Varicella Vaccine Market.
Which is the fastest growing region in Global Varicella Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Varicella Vaccine Market?
In 2024, the North America accounts for the largest market share in Global Varicella Vaccine Market.
What years does this Global Varicella Vaccine Market cover?
The report covers the Global Varicella Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Varicella Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Varicella Vaccine Industry Report
Statistics for the 2023 Varicella Vaccine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Varicella Vaccine analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
